ADVANCING COMBINATION INTRATUMORAL IMMUNOTHERAPY
Syncromune is uniquely focused on developing intratumoral immunotherapy to fight cancer in a new way
A novel approach to fighting metastatic cancers
Syncromune™ is a privately held, clinical stage biopharmaceutical company dedicated to the development of novel intratumoral immunotherapies for metastatic solid tumors. We are at the forefront of developing combination immunotherapies, which several thought leaders consider to be the future of cancer therapy. We are committed to bringing life-changing treatments to patients with unmet medical needs by fighting cancer in a new way.
The company is currently developing Syncrovax™, a proprietary platform technology that uses a combination approach to synchronize the timing and location of tumor antigen release with the functional activation of immune cells. A vaccine is created from the patient’s own tumor, making it a personalized treatment for each patient. The platform is designed to enable the immune system to recognize and attack cancer throughout the body. Several clinical development programs are underway to advance Syncrovax™ into clinical trials.
Fort Lauderdale, FL
Combination Intratumoral Immunotherapy
58 Patents Pending & Granted*
*As of 6/14/2022
is to be the world leader in optimized intratumoral immuno-oncology multi-component drug development and therapies.
Unsurpassed Dedication to Finding a Cure
To deliver on the promise of our novel immunotherapy platform, we have assembled a senior leadership team with multi-disciplinary expertise in drug development, cancer immunotherapy, combination drug/device cancer therapy & clinical trials.
CHARLES J. LINK, MD
Executive Chairman & Chief Medical Officer
President & Chief Executive Officer
Chief Financial Officer
MARIO MAUTINO, PHD
Chief Scientific Officer
Chief Business Officer
EVP, Regulatory Affairs – Medical Device
GABRIELA ROSSI, PHD
EVP, Immunology & Grant Management
EVP, Clinical Affairs
STEPHEN KEE, MD
EVP, Clinical Operations
EVP, Medical Device Development
EVP, Investor Relations & Corporate Communications
Disclaimers: The content on this website is intended for US healthcare professionals only. The compounds and their uses mentioned on this website are investigational and have not been determined safe and effective by the US Food and Drug Administration.